BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease
Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients.
Stocktwits
More News
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?
Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.
Stocktwits
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.read more...
Benzinga
Why Is Pharvaris Stock Soaring Tuesday?
Pharvaris (PHVS) stock surges 17% on positive Phase 3 HAE trial data. Deucrictibant XR reduced monthly attacks up to 87%.read more...
Benzinga
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet
The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy
Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade
The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Pharvaris (PHVS) Expected to Announce Earnings on Tuesday
Pharvaris (NASDAQ:PHVS) will be releasing earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-pharvaris-nv-stock...
MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold ra...
MarketBeat
Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 21,700 Shares of Stock
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Anne Lesage sold 21,700 shares of the firm's stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of...